Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.
Do you have ovarian, peritoneal, or fallopian tube cancer that came back after receiving standard therapy? If so, you might be able to take part in a study that looks at a new treatment, iC9.CAR.B7-H3 cells, to test the safety of these cells and observe any side effects.
Do you have Stage II or III Breast cancer? If you have enough tissue from your breast cancer diagnosis to send for Mammaprint genomic testing, you may be able to take part in this research study. In this study, we want to learn more about adding an immunotherapy drug, durvalumab, to your chemotherapy treatment. The Mammaprint testing is conducted at no cost to you and the cost of durvalumab is covered.
Do you have intermediate risk prostate cancer and don't want to undergo surgery? You may be able to participate in a research study comparing therapy based on genetic testing.
Have you been diagnosed with Lateralized Oropharyngeal Cancer . If so, you may be able to take part in a research study looking at the safety by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT) compared to the usual treatment when radiotherapy is given .
Do you have Non-Small Cell Lung Cancer? Have you previously been treated with Osimertinib? If so, you may be eligible for a trial comparing osimertinib in combination with other medications to treat your lung cancer. Please reach out if you're interested!
Have you been diagnosed with early stage triple negative breast cancer? We are asking you to take part in this research study because you have been diagnosed with triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with pembrolizumab, followed by breast surgery. The chemotherapy plus pembrolizumab produced a pathologic complete response (pCR), meaning that no remaining cancer was found during your breast surgery.
Have you been diagnosed with breast cancer? If so, you may be able to take part in a research study for the collection of tumor specimens and genomic DNA from patients with early or metastatic breast cancer.
Do you have stages 3-5 advance melanoma that is unresectable? Are you currently receiving standard therapy for your cancer? You may be able to participate in a research study to help us find out if your length of treatment could be reduced.
Do you Patients with have Advanced Nasopharyngeal Carcinoma that has Progressed After Platinum Treatment and Immunotherapy? If so, you may be able to participate in a research study to find out if progression-free survival of the triplet combination (CaboNivoIpi) is more favorable than the doublet (NivoIpi).